查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138330

全球脑膜炎球菌疫苗市场 - 2022-2029

Global Meningococcal Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

脑膜炎球菌疫苗的市场驱动力是对脑膜炎球菌疫苗的需求不断增加和脑膜炎患病率不断上升。

脑膜炎球菌是脑膜炎的病原体，脑膜炎是一种类似于普通流感的严重疾病，以发烧、呕吐和头痛为特征。然后细菌穿过身体并迅速繁殖，最终到达血液、神经和大脑。脑膜炎是一种类似于流感的以发热、呕吐和头痛为特征的严重疾病，脑膜炎的病原体是脑膜炎球菌。然后细菌穿过身体并迅速繁殖，最终到达血液、神经和大脑。开发针对 B 型脑膜炎球菌的疫苗是现代医学的一个分水岭。 B 型脑膜炎球菌是美洲、加拿大、欧洲、亚洲和其他几个地区疾病的主要原因。 2020 年 7 月 1 日，脑膜炎球菌 B 疫苗 (Vexelo) 和脑膜炎球菌 ACWY 疫苗 (Nimenrix) 将被批准用于所有年龄段的患有某些会增加 IMD 风险的医疗条件的人的 NIP。此外，2020 年 4 月 24 日，FDA 批准了用于预防 2 岁及以上人群侵袭性脑膜炎球菌疾病的“MENQADFFY 脑膜炎球菌（A、C、Y、W 组）结合疫苗”批准了生物製剂许可申请。因此，对脑膜炎球菌疫苗的需求增加有望推动市场增长。

与脑膜炎球菌疫苗相关的副作用预计会阻碍市场增长。

大约一半的 MenACWY 疫苗接种者会出现轻微的副作用，例如注射部位发红、注射部位疼痛、肌肉酸痛和头痛。 Menomune 疫苗包含四种最常见的脑膜炎球菌菌株。 Menomune 通常会在註射部位引起疼痛、发红、肿胀、压痛和肿块，通常持续 1-2 天。

CDC 报告说，大约一半接受脑膜炎球菌结合疫苗的人在註射部位会出现轻微的副作用，例如发烧、发红和疼痛。

行业分析

脑膜炎球菌疫苗市场根据各种行业因素（包括未满足的需求、定价分析、供应链分析和监管分析）对市场进行深入分析。

COVID-19 影响分析

在大流行的早期阶段，许多国家暂停了疫苗接种计划，以降低传播 SARS-CoV-2 的风险。由于 COVID-19，许多疫苗接种计划将被取消。在许多其他国家，免疫计划并未停止，但遏制措施减缓了疫苗的接种速度（父母不知道是否正在接种疫苗，学校普遍停课和预约困难）。在八个国家（美国、英国、意大利、法国、德国、阿根廷、巴西和澳大利亚）进行的一项研究发现，在 COVID-19 大流行期间，近一半的父母曾计划让孩子患脑膜炎。结果他有推迟或取消他的疫苗接种预约。封锁限制 (63%) 和对 SARS-CoV-2 传播的担忧 (33%) 是此次疫苗接种中断的主要原因。

全球脑膜炎球菌疫苗市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 预计对脑膜炎球菌疫苗的需求不断增长将推动市场增长。
    • 限制因素
      • 与脑膜炎球菌疫苗相关的副作用预计会阻碍市场增长。
    • 机会
    • 影响分析

第5章行业分析

  • 波特的五种力量
  • 未满足的需求
  • 供应链
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 结合疫苗
  • 多醣疫苗
  • 联合疫苗
  • 其他

第 8 章血清分型

  • 男士 ACWY
  • 男装B/BC
  • 男装
  • 男士空调
  • 男装

第 9 章，最终用户

  • 医院
  • 诊所
  • 疫苗接种中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • 赛诺菲巴斯德公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bio-Manguinhos
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bio-Med Pvt Ltd
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co., Ltd
  • Incepta Pharmaceuticals Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
简介目录
Product Code: DMPH1532

Market Overview

Meningococcal Vaccines Market is expected to grow at a high CAGR of 12% during the forecasting period (2022-2029).

Meningococcal vaccines are designed to safeguard against Neisseria meningitidis infection. Vaccines available target certain meningococcus strains such as A, B, C, W-135, and Y. On average, the vaccines provide 80 percent to 100 percent immunity for two years, with some requiring booster doses. The vaccinations could be monovalent, targeting a specific kind of meningococcus, or multivalent.

Market Dynamics

The meningococcal vaccines market factors are the increase in demand for meningococcal vaccines and the increasing prevalence of meningitis.

The increase in demand for meningococcal vaccines is expected to drive market growth.

Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, like the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, similar to the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Developing a vaccine against meningococcus B is a watershed moment in modern medicine. Meningococcus B is a leading cause of disease in the Americas, Canada, Europe, Asia, and several other regions. On July 1, 2020, the meningococcal B vaccine (Bexsero) and the meningococcal ACWY vaccine (Nimenrix) were funded under the NIP beginning for people of all ages with certain medical conditions that increase their risk of IMD. Furthermore, on April 24, 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older. Hence, increasing demand for meningococcal vaccines is expected to boost the market growth.

The side effects associated with meningococcal vaccines are expected to hamper the market growth.

Approximately half of those who received a MenACWY vaccine experienced mild side effects, such as redness where the shot was administered, soreness in the area where the shot was administered, muscle aches, and headache. Four of the most common types of meningococcal bacteria are included in the menomune vaccine. Menomune commonly causes pain, redness, swelling, tenderness, or a lump at the injection site, usually lasting 1-2 days.

The CDC reports that roughly half of those who receive a meningococcal conjugate vaccine experience mild side effects, such as fever, redness, and pain where the shot was administered.

Industry Analysis

The meningococcal vaccines market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

During the early stages of the pandemic, many countries suspended immunization programs to reduce the risk of spreading SARS-CoV-2. Many vaccination programs are halted due to COVID-19. Although vaccination programs did not cease in many other countries, vaccine uptake slowed due to containment measures (parents were uncertain about whether vaccinations were taking place and experienced difficulties booking appointments with widespread school closures). According to studies conducted in eight countries (the United States, the United Kingdom, Italy, France, Germany, Argentina, Brazil, and Australia), approximately half of parents delayed or canceled a scheduled meningococcal vaccination appointment for their child during the COVID-19 pandemic. The main reasons for this vaccination disruption are lockdown regulations (63%) and concerns about contracting SARS-CoV-2 (33%).

Segment Analysis

The conjugate vaccines segment is expected to hold the largest market share in the meningococcal vaccines market.

Meningococcal conjugate (MenACWY) vaccine protects against four types of Neisseria meningitidis bacteria (serogroups A, C, W, and Y). It is appropriate for all children and teenagers aged 11 and up. Some types of MenACWY are given to younger children (as young as 8 weeks) if they are at a higher risk of contracting meningococcal disease. Conjugate vaccine technology has been used successfully in childhood vaccines to prevent other bacterial meningitis pathogens, such as vaccines against Haemophilus influenzae serotype b (Hib) and, more recently, seven- and nine-valent conjugate pneumococcal vaccines. Meningococcal conjugate vaccines against N. meningitidis serogroup C are highly effective in young children and adolescents, with few side effects.

There are currently four quadrivalent meningococcal conjugate vaccine formulations available globally. All contain MenA, MenC, MenW, and MenY capsular polysaccharides, but the type of carrier protein varies. MenACWY-D (Menactra, Sanofi Pasteur) is conjugated to diphtheria toxoid (D), MenACWY-CRM (Menveo, GSK) is conjugated to CRM, and two MenACWY-TT vaccines, Nimenrix (Pfizer) and the recently available MenQuadfi are conjugated to TT (Sanofi Pasteur). Furthermore, On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

Geographical Analysis

North American region is expected to hold the largest market share in the global meningococcal vaccines market.

The rising prevalence of meningitis is expected to drive up demand for meningitis vaccines, resulting in rapid market growth. Various pathogens can cause meningitis, but bacterial meningitis has the highest global burden. According to the National Meningitis Association (NMA), approximately 600-1,000 people in the United States contract meningococcal disease each year. Furthermore, preteens, teens, and young adults account for 21% of meningococcal disease cases.

Furthermore, the growing public awareness of the disease is expected to drive market growth in this region. The Meningitis Foundation of America (MFA) is a non-profit organization in the United States dedicated to providing information and support to people with personal experiences with meningitis. This foundation also aims to raise public and medical awareness about the early symptoms of meningitis. As a result, the meningococcal vaccine market is expected to grow steadily over the forecast period.

Competitive Landscape

Major key players in the meningococcal vaccines market are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur Inc., Serum Institute of India Ltd., Walvax Biotechnology Co., Ltd, Incepta Pharmaceuticals Ltd., Chongqing Zhifei Biological Products Co., Ltd.

Sanofi Pasteur Inc.:

Overview:

Sanofi Pasteur is the world's largest company solely dedicated to vaccines. The vaccines division of the French multinational pharmaceutical company Sanofi is known as Sanofi Pasteur. The company's business is divided into pharmaceuticals, chemicals, vaccines, and consumer healthcare.

Product Portfolio:

MenQuadfi is a vaccine given to people aged 2 to help prevent invasive meningococcal disease (including meningitis) caused by the bacterium N meningitides serogroups A, C, W, and Y. Serogroup B disease is not prevented by MenQuadfi.

Key Developments:

On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

The global meningococcal vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in demand for meningococcal vaccines is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with meningococcal vaccines are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Conjugate Vaccines*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Polysaccharide Vaccines
  • 7.4. Combination Vaccines
  • 7.5. Others

8. By Serotype

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 8.1.2. Market Attractiveness Index, By Serotype Segment
  • 8.2. MenACWY*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. MenB/BC
  • 8.4. MenC
  • 8.5. MenAC
  • 8.6. MenA

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Clinics
  • 9.4. Vaccination Centre
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sanofi Pasteur Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Manguinhos
  • 12.3. GlaxoSmithKline plc
  • 12.4. Merck & Co., Inc.
  • 12.5. Pfizer Inc.
  • 12.6. Bio-Med Pvt Ltd
  • 12.7. Serum Institute of India Ltd.
  • 12.8. Walvax Biotechnology Co., Ltd
  • 12.9. Incepta Pharmaceuticals Ltd.
  • 12.10. Chongqing Zhifei Biological Products Co., Ltd.